Join the Oncology Voice Network. Join for Free
Role of the MSL in launch preparedness for new products and indications
MSL roles drug launch preparation medical affairs strategy pharmaceutical trends field medical leadership

Role of the MSL in launch preparedness for new products and indications


Share This Article


Summary

Matt Goodwin joins Tom Caravela to discuss the crucial role of MSLs in drug launch preparation and leadership. Matt shares his career journey and insights from his experiences at MAPS. They delve into the training, expectations, and success factors for MSLs during launches, addressing common stressors and establishing key milestones. The conversation highlights common pitfalls and offers advice for MSLs navigating launch phases. They examine the skills and motivation needed for evaluating MSL candidates and discuss future trends in pharma and MSL roles. The episode concludes with a call for listener feedback and subscription.

Matt Goodwin, Vice President Medical Affairs at SC Pharmaceuticals discusses the role of the MSL in preparation and strategy for launch preparedness of new products/indications.

Learn more about…

👉 The importance of preparation and timeline for launch
👉 Training and resources for launch mode
👉 The role of field medical leadership
👉 Milestones and success factors to consider
👉 The stressors to be aware of and anticipate during a launch

Click for Source
MSL roles, drug launch preparation, medical affairs strategy, pharmaceutical trends, field medical leadership

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
No “D”…No Problem: Finding Success WITHOUT a Doctorate
Partner Avatar MSL Talk: Tom Caravela, Greg Auclair

No “D”…No Problem: Finding Success WITHOUT a Doctorate

Podcast
Motivation Means NOTHING…
Partner Avatar MSL Talk: Tom Caravela

Motivation Means NOTHING…

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN